{"task_id": "4bb8b4e7664e3600", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 222/464)", "text": "be use\nful for bone metastasis\nProstate Cancer\n211\n\n--- Page 233 ---\nTREATMENT ISSUES\nCOMPARISON OF TREATMENTS FOR LOCALIZED DISEASEa\nImpotence\nUrinary incontinence\nUrinary irritation\nGI irritation\nProstatectomyb\n50 90%\n10 20%\n15 60%\n2 17%\nBrachytherapy\n50%\n1 2%\n12 30%\n10%\nExternal RTc\n50%\n1 2%\n2 30%\n30%\na side effects at 5 years are listed\nb symptoms tend to decrease over time\nc symptoms tend to increase over time\nRADICAL PROSTATECTOMY\n\u0002\nBENEFITS\n5 year disease free survival 85%\n\u0002\nINDICATIONS\npreferred for patients with low risk\ndisease, life expectancy >20 years, or significant\nurinary symptoms\n\u0002\nCONTRAINDICATIONS\nage >70, high risk disease\n\u0002\nADVERSE\nEFFECTS\nurinary (frequency, urgency,\nnocturia, dysuria, incontinence), impotence\nBRACHYTHERAPY\nimplant of radioactive seeds\n\u0002\nBENEFITS\n5 year disease free survival 96%\n\u0002\nINDICATIONS\neligibility\ncriteria\ninclude\nPSA\n\u000415 ng/mL, Gleason score \u00047, stage \u0004T2c, pros\ntate volume \u000460 mL, and life expectancy >5 years\n\u0002\nCONTRAINDICATIONS\nsignificant urinary symptoms\n(as prostate swells significantly shortly after proce\ndure), prior TURP\n\u0002\nADVERSE\nEFFECTS\nurinary (frequency, urgency,\nnocturia, dysuria, incontinence), GI (diarrhea,\ntenesmus), and impotence; 3% require indwelling\nurinary catheter for >3 weeks and <1% chance of\nsevere GI symptoms requiring colostomy. The\nsymptoms typically peak at 6 weeks and generally\nresolve over time; 50% of patients return to base\nline symptoms at 3 months and 95% by 1 year\nEXTERNAL BEAM RADIATION\n\u0002\nBENEFITS\n5 year disease free survival 80%\nTREATMENT ISSUES (CONT\u2019D)\n\u0002\nINDICATIONS\npreferred for patients with high risk\ndisease or older\n\u0002\nCONTRAINDICATIONS\npelvic kidney, inflammatory\nbowel disease, connective tissue disease (SLE,\nscleroderma), or prior radiation to same region\n\u0002\nADVERSE\nEFFECTS\nurinary (frequency urgency,\nnocturia, dysuria, incontinence), GI (diarrhea, rectal\nbleeding), and impotence. Urethral stricture (1%),\nbowel obstruction (0.1%). Also risk of late onset\nsecond malignancy\nLHRH AGONISTS\n\u0002\nINDICATIONS\nhigh intermediate or high risk loca\nlized disease, salvage setting, or advanced disease\nsetting. Requires the use of an antiandrogen (fluta\nmide) for first few weeks to counter flare response\n\u0002\nADVERSE\nEFFECTS\nfatigue,\nhot\nflushes,\nmood\nchanges, weight gain, decreased libido, impotence,\ngynecomastia, and over the long term decreased\nmuscle mass, anemia, and osteoporosis. All patients\ninitiated on LHRH agonists should have baseline\nbone density scan and be started on calcium and\nvitamin D supplements. Bisphosphonates should be\ngiven if osteoporosis confirmed by bone density scan\nTIME LINE\nmedian time from castration to andro\ngen independence 1.5 year. Median time from andro\ngen independence to death 1.5 year\nTesticular Cancer\nEGCCCG Guidelines Ann Onc 2004 15\nPATHOPHYSIOLOGY\nCLASSIFICATION BY HISTOLOGY\n\u0002\nTESTICULAR INTRAEPITHELIAL NEOPLASIA (TIN)\n70%\nchance of progression to testicular cancer in 7 years\n\u0002\nGERM CELL TUMOR (95%)\ncan differentiate into any\nimmature or mature tissue type, usually mixed\n\u0002\nSEMINOMA (40%)\nneoplastic counterpart of\nspermatocyte. Age thirties to forties, pure, aFP\nnega4tive and sometimes slightly bhCG posi\ntive. Few metastasize. Very radiosensitive and\nvery chemosensitive\n\u0002\nNON-SEMINOMA (60%)\nage twenties to thirties,\npure or mixed, more metastasize. Chemosensi\ntive. Include the following subtypes\nPATHOPHYSIOLOGY (CONT\u2019D)\n\u0002\nEMBRYONAL\nCELL\nCARCINOMA\nneoplastic\ncounterpart of inner cell mass of embryo.\nMay be bhCG+, aFP+\n\u0002\nYOLK SAC TUMOR\nneoplastic counterpart of\nyolk sac. Usually aFP+\n\u0002\nCHORIOCARCINOMA\nneoplastic\ncounterpart\nof chorionic villus. Usually bhCG+\n\u0002\nIMMATURE TERATOMA\nneoplastic counterpart\nof fetal tissue. Marker negative\nTREATMENT ISSUES (CONT\u2019D)\n\u0002\nMATURE TERATOMA\nneoplastic counterpart of\nmature adult tissue. Marker negative. Com\npletely resistant to chemotherapy. May trans\nform into malignant mesodermal, endoder\nmal, or ectodermal elements\n212\nTesticular Cancer", "text_length": 3955, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 222/464)", "type": "chunk", "chunk_index": 221, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.551919", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.552967", "status": "complete", "chunks_added": 3}